Liminatus Pharma LLC 宣布了一项资本结构调整方案。根据协议,该公司将向特定权证持有者发行总计400万股普通股。作为交换,持有者需交回并注销其持有的805,377份认股权证。
此项交易旨在优化公司的资本结构,并简化股权工具。通过以股份置换权证,公司可以巩固股权基础,并可能减少未来因权证行权导致的潜在股权稀释。
Liminatus Pharma LLC 宣布了一项资本结构调整方案。根据协议,该公司将向特定权证持有者发行总计400万股普通股。作为交换,持有者需交回并注销其持有的805,377份认股权证。
此项交易旨在优化公司的资本结构,并简化股权工具。通过以股份置换权证,公司可以巩固股权基础,并可能减少未来因权证行权导致的潜在股权稀释。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.